Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT).
Alexander EJ, Murray JR, Morgan VA, Giles SL, Riches SF, Hazell S, Thomas K, Sohaib SA, Thompson A, Gao A, Dearnaley DP, DeSouza NM. Alexander EJ, et al. Among authors: gao a. Radiother Oncol. 2019 Dec;141:181-187. doi: 10.1016/j.radonc.2019.07.030. Epub 2019 Sep 5. Radiother Oncol. 2019. PMID: 31493904 Free PMC article.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.
Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E. Dearnaley D, et al. Among authors: gao a. Lancet Oncol. 2012 Jan;13(1):43-54. doi: 10.1016/S1470-2045(11)70293-5. Epub 2011 Dec 12. Lancet Oncol. 2012. PMID: 22169269 Free article. Clinical Trial.
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E. Wilkins A, et al. Among authors: gao a. Lancet Oncol. 2015 Dec;16(16):1605-16. doi: 10.1016/S1470-2045(15)00280-6. Epub 2015 Oct 28. Lancet Oncol. 2015. PMID: 26522334 Free PMC article. Clinical Trial.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators. Dearnaley D, et al. Among authors: gao a. Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20. Lancet Oncol. 2016. PMID: 27339115 Free PMC article. Clinical Trial.
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
Reis Ferreira M, Khan A, Thomas K, Truelove L, McNair H, Gao A, Parker CC, Huddart R, Bidmead M, Eeles R, Khoo V, van As NJ, Hansen VN, Dearnaley DP. Reis Ferreira M, et al. Among authors: gao a. Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1234-1242. doi: 10.1016/j.ijrobp.2017.07.041. Epub 2017 Aug 2. Int J Radiat Oncol Biol Phys. 2017. PMID: 28939224 Free PMC article. Clinical Trial.
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE Trial.
Murray JR, Tree AC, Alexander EJ, Sohaib A, Hazell S, Thomas K, Gunapala R, Parker CC, Huddart RA, Gao A, Truelove L, McNair HA, Blasiak-Wal I, deSouza NM, Dearnaley D. Murray JR, et al. Among authors: gao a. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):715-724. doi: 10.1016/j.ijrobp.2019.11.402. Epub 2019 Dec 5. Int J Radiat Oncol Biol Phys. 2020. PMID: 31812718 Free article. Clinical Trial.
Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
Brand DH, Brüningk SC, Wilkins A, Fernandez K, Naismith O, Gao A, Syndikus I, Dearnaley DP, Tree AC, van As N, Hall E, Gulliford S; CHHiP Trial Management Group. Brand DH, et al. Among authors: gao a. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):596-608. doi: 10.1016/j.ijrobp.2020.12.041. Epub 2021 Jan 4. Int J Radiat Oncol Biol Phys. 2021. PMID: 33412260 Free PMC article. Clinical Trial.
The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial.
Brand DH, Brüningk SC, Wilkins A, Naismith O, Gao A, Syndikus I, Dearnaley DP, van As N, Hall E, Gulliford S, Tree AC; CHHiP Trial Management Group. Brand DH, et al. Among authors: gao a. Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):327-336. doi: 10.1016/j.ijrobp.2022.08.030. Epub 2022 Aug 17. Int J Radiat Oncol Biol Phys. 2023. PMID: 35985457 Free article. Clinical Trial.
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial.
Tree AC, Satchwell L, Alexander E, Blasiak-Wal I, deSouza NM, Gao A, Greenlay E, McNair H, Parker C, Talbot J, Dearnaley D, Murray J. Tree AC, et al. Among authors: gao a. Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):305-316. doi: 10.1016/j.ijrobp.2022.09.058. Epub 2022 Sep 21. Int J Radiat Oncol Biol Phys. 2023. PMID: 36150450 Clinical Trial.
1,397 results